Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Charles River Laboratories Intl. IncTrade
Rivian Automotive, Inc.Trade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Rivian Automotive, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $230.41 (market cap $11.14B), while Rivian Automotive, Inc. trades at $17.95 (market cap $25.33B). The key difference: Rivian Automotive, Inc. is far larger — about 2.3× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.

CRLRIVN
Market Cap
$11.14B$25.33B
Sector
HealthConsumer Cyclical
52-Week High
$233.60$22.45
52-Week Low
$145.57$11.64
Enterprise Value
$14.00B$27.07B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Rivian Automotive, Inc.

Rivian Automotive (RIVN) trades at $17.31, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $19.22. The company has beaten EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -63.62%. Recent news highlights the potential of the R2 vehicle launch and a $1.74 billion stock offering to fund expansion, creating mixed investor sentiment amid growth prospects and dilution concerns.

The outlook hinges on R2 success and path to profitability, offering upside if execution improves, but high cash burn, competitive pressures, and shareholder dilution present significant risks. Analyst consensus is cautiously optimistic with 44.83% buy ratings, but the stock faces volatility around earnings and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Rivian Automotive, Inc.

Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.

Read more on RIVN